Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 362, Issue 18, Pages 1663-1674Publisher
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMoa0910496
Keywords
-
Categories
Funding
- Abbott Vascular
- TherOx
- Medicines Company
- Atrium
- Osprey Medical
- IntraReDx
- Reva Medical
- Merck
- CoreValve
- Boston Scientific
- St. Jude Medical, Edwards
- Volcano
- Accelerated Technologies
- Radiant Medical
- AstraZeneca
- Prescient Medical
- Medtronic
- Eli Lilly
- Bristol-Myers Squibb
- Bingen idec
- XTENT
- Bioabsorbable Therapeutics
- Asten BioPharma
- SB Medical
- Ovalum and Biosensors
Ask authors/readers for more resources
Background: Previous studies have established the superiority of coronary everolimus-eluting stents over paclitaxel-eluting stents with respect to angiographic findings. However, these trials were not powered for superiority in clinical end points. Methods: We randomly assigned 3687 patients at 66 U.S. sites to receive everolimus-eluting stents or paclitaxel-eluting stents without routine follow-up angiography. The primary end point was the 1-year composite rate of target-lesion failure (defined as cardiac death, target-vessel myocardial infarction, or ischemia-driven target-lesion revascularization). Results: Everolimus-eluting stents were superior to paclitaxel-eluting stents with respect to the primary end point of target-lesion failure (4.2% vs. 6.8%; relative risk, 0.62; 95% confidence interval, 0.46 to 0.82; P=0.001). Everolimus-eluting stents were also superior with respect to the major secondary end point of the 1-year rate of ischemia-driven target-lesion revascularization (P=0.001) and were noninferior with respect to the major secondary end point of the 1-year composite rate of cardiac death or target-vessel myocardial infarction (P<0.001 for noninferiority; P=0.09 for superiority). The 1-year rates of myocardial infarction and stent thrombosis were also lower with everolimus-eluting stents than with paclitaxel-eluting stents (1.9% vs. 3.1%, P=0.02 for myocardial infarction; 0.17% vs. 0.85%, P=0.004 for stent thrombosis). Target-lesion failure was consistently reduced with everolimus-eluting stents as compared with paclitaxel-eluting stents in 12 prespecified subgroups, except in the subgroup of patients with diabetes (6.4% vs. 6.9%, P=0.80). Conclusions: Everolimus-eluting stents, as compared with paclitaxel-eluting stents, resulted in reduced rates of target-lesion failure at 1 year, results that were consistent in all patients except those with diabetes, in whom the results were nonsignificantly different. (ClinicalTrials.gov number, NCT00307047.) N Engl J Med 2010;362:1663-74.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available